Insider buying last 90 days
No open-market insider purchases were filed for LQDA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LQDA insider filing, plotted on the chart in Gekko.Open LQDA in Gekko
NASDAQ: LQDA
Liquidia (LQDA) Stock Analysis & Forecast
Sep 28 close
$73.67+5.24 (+7.7%)
Gekko Brief
AI summaryLiquidia shares rose 7.7% to $73.67 this week, with attention on Yutrepia's continued sales growth amid intensifying competition from established and emerging PAH therapies. Wall Street brokerages maintain an average "Hold" recommendation with a 12-month price target of $98.08, following the company's reported year-over-year revenue growth of 1842.1% to $171.68 million, though quarterly EPS of $0.74 slightly missed estimates.
The stock trades between its 50-day average of $75.50 and 200-day average of $54.07, reflecting a mixed trend picture. The GekkoIndex reads 55.2, placing it in the Neutral zone. Price sits 16.6% below Gekko Fair Value of $88.32, a gap that leaves room on the downside relative to that benchmark.
Liquidia's next earnings report is scheduled for 2 November, 34 days out, placing it outside a typical 20-trading-day holding window. Over the last 30 days, 2 unusual options signals were recorded, with call premium of $1,111,084 against put premium of $41,412. One trailblazer holder is noted among smart-money activity. Seasonally, the next 20 trading days have averaged +5.5% over 5 years, rising in 2 of those years. Consensus among 7 analysts stands at 5 buy and 2 hold ratings, with a consensus target of $107.75, implying 46.3% upside from current levels.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Liquidia price vs fair value
Close $73.67200-day averageGekko Fair Value $88.32
Liquidia quick facts
- Market cap
- $6.55B
- P/E ratio
- 48.9
- Forward P/E
- 10.5
- EPS, TTM
- $1.40
- Revenue, TTM
- $450.9M
- Profit margin
- 30.7%
- Dividend yield
- —
- Beta
- 0.54
- Volume
- 1.20M avg 1.22M
- 1-year return
- +228.2%
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±11.3%
- 50-day average
- $75.50
- 200-day average
- $54.07
- Next earnings
- Nov 2 before open
- Shares outstanding
- 89.51M
Liquidia swing-trade checklist
Liquidia scores 3 supportive, 3 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive3 mixed0 headwinds
- Trendmixed
Averages disagree
Close $73.67 sits between the 50-day ($75.50) and 200-day ($54.07) averages, or the averages disagree.
See the chart - GekkoIndexmixed
55.2, Neutral
Reading 55.2 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
16.6% below
Price is 16.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 2 unusual options signals.
See smart money - Earnings risksupportive
Reports in 34 days
Next report Nov 2, 2026, 34 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+5.5% on average
From this point in the calendar, the next 20 trading days averaged +5.5% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Liquidia stock chart and price history
Liquidia closed at $73.67 on Sep 28, 2026, +228.2% over the past year, inside a 52-week range of $21.15 to $93.61.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +5.3%
- 3 months
- −1.9%
- 6 months
- +110.3%
- 1 year
- +228.2%
The full LQDA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LQDA in Gekko
Follow Liquidia through every session
Put LQDA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LQDA in GekkoFree for 7 days. No credit card required.
About Liquidia
Liquidia works in biopharmaceuticals, creating, manufacturing, and bringing to market treatments meant to address important unmet needs among patients across the United States. Among its development efforts, the company is working on YUTREPIA, an inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension. This program represents a central piece of its pipeline.
Alongside its work on new treatments, Liquidia also sells a generic injectable version of treprostinil to patients in the U.S. market, giving the company both a commercial product and a pipeline asset aimed at the same underlying condition.
Liquidia was established in 2004 and keeps its headquarters in Morrisville, North Carolina. Its shares trade on the NASDAQ under the ticker LQDA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- liquidia.com
Liquidia GekkoIndex: the smart money zone
Liquidia’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.2, in the Neutral zone, down 11.5 points over five sessions.
55.2Neutral
Down 11.5 points over five sessions, from the Accumulation zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 12 | +8.5% | +19.6% | ||
| Accumulation | 201 | +2.5% | +7.5% | ||
| Neutral (current zone) | 403 | +1.5% | +6.4% | ||
| Distribution | 50 | −1.3% | +5.2% | ||
| Selling | 6 | Too few readings yet | |||
Average LQDA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the LQDA price, zone by zone.Track LQDA in Gekko
Is Liquidia stock overvalued? Gekko Fair Value
Liquidia trades 16.6% below Gekko Fair Value of $88.32, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Liquidia shares are worth, recalculated every trading day.
$88.32
Gekko Fair Value, Sep 26, 2026
16.6% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open LQDA in Gekko
Liquidia insider and Congress trading
No open-market insider purchases were filed for Liquidia, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in LQDA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for LQDA, plotted on the chart in Gekko.Open LQDA in Gekko
Unusual options activity last 30 days
2signals, 96% of the flagged premium in calls.
Latest: Bullish flow on Sep 17, $783K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds LQDA.
0added0opened1trimmed2sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Liquidia earnings: next date and track record
Liquidia reports on Nov 2, 2026, before the open (34 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 2, 2026
Expected before the open, 34 days away
- EPS estimate
- $0.90
- Revenue estimate
- $205.9M
3 of 8reports beat the EPS estimate
±12.8%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 12, 2026 AI summary
- What they said
- YUTREPIA reached ~5,900 unique patient prescriptions and 5,000+ patient starts within one year of launch, with 1,100+ prescribing physicians. Net revenue approaches 30% of the inhaled treprostinil market as Q2 market grew to $607M from $573M in Q1. YUTREPIA's growth exceeded total category growth. ASCENT study showed progressive 6MWD improvements of 21.5, 31.5, and 41 meters at weeks 8, 16, and 24. Pipeline candidate L606 (twice-daily) shows strong tolerability data with lowest cough incidence reported.
- Guidance
- Management plans 10 clinical studies underway or starting within 12 months across YUTREPIA and L606. Business now generates sufficient cash flow to self-fund R&D investments. No specific revenue or EPS targets were provided in this excerpt.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 12, 2026 | $0.74 est $0.76 | $171.7M est $168.5M | −18.1% |
| May 11, 2026 | $0.52 est $0.34 | $132.9M est $119.4M | +33.8% |
| Mar 5, 2026 | $0.15 est $0.08 | $92.02M est $88.59M | +4.8% |
| Nov 3, 2025 | −$0.04 est −$0.45 | $54.34M est $80.72M | +14.6% |
| Aug 12, 2025 | −$0.49 est −$0.43 | $8.84M est $14.30M | +18.9% |
| May 8, 2025 | −$0.45 est −$0.42 | $3.12M est $4.16M | −1.7% |
| Mar 19, 2025 | −$0.46 est −$0.38 | $2.92M est $3.31M | +4.7% |
| Nov 13, 2024 | −$0.39 est −$0.37 | $4.45M est $4.63M | −5.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Liquidia stock forecast and analyst price targets
Analysts’ average 12-month price target for Liquidia is $107.75, +46.3% from the last close, from 7 firms rating the stock in the last 90 days.
$107.75consensus 12-month target, +46.3% from the last close
Now $73.67Avg $107.75
Low $90High $130
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 8 | Wells Fargo | $108 | +46.6% |
| Sep 2 | Wells Fargo | $108 | +46.6% |
| Aug 19 | Wells Fargo | $108 | +46.6% |
| Aug 14 | H.C. Wainwright | $130 | +76.5% |
| Aug 13 | Raymond James | $106 | +43.9% |
+6.4%average 20-day move after past Neutral readings
+5.5%average move over the next 20 trading days in the last 5 years
±4.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Liquidia seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Liquidia averaged +5.5% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.3% | 4 of 5 |
| Next 10 trading days | +6.8% | 4 of 5 |
| Next 15 trading days | +8.1% | 3 of 5 |
| Next 20 trading days | +5.5% | 2 of 5 |
| Next 30 trading days | +14.5% | 3 of 5 |
For scale, LQDA’s typical 20-trading-day move in either direction is about 11.3%.
Liquidia market cap and key statistics
Liquidia’s market cap is $6.55B, with a P/E ratio of 48.9 and revenue of $450.9M over the last twelve months.
Valuation
- Market cap
- $6.55B
- P/E ratio
- 48.9
- Forward P/E
- 10.5
- EPS, TTM
- $1.40
- Gekko Fair Value
- $88.32
Trading
- Volume
- 1.20M
- Avg volume, 20 days
- 1.22M
- 52-week high
- $93.61
- 52-week low
- $21.15
- Shares outstanding
- 89.51M
Financials
- Revenue, TTM
- $450.9M
- Profit margin
- 30.7%
- Return on equity
- 131.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.54
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±11.3%
Liquidia stock news this week
4 headlines about Liquidia from the past week, newest first, each linking to the publisher.
- Is It Too Late to Buy Liquidia Corp (LQDA) After 7.7% Rally? GF Value Says UndervaluedGuruFocus, Sep 28
- Liquidia Corporation (NASDAQ:LQDA) Stock Rated "Hold" by Wall Street BrokeragesMarketBeat, Sep 28
- Form 144 LIQUIDIA CORPORATION For: 22 September By Investing.comInvesting.com Canada, Sep 23
- Can LQDA's Yutrepia Outpace Intensifying PAH Competition?Zacks Investment Research, Sep 23
Liquidia peers
Liquidia’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Liquidia stock FAQ
What is Liquidia’s market cap?
Liquidia’s market cap is $6.55B at the Sep 28, 2026 close of $73.67, with 89.51M shares outstanding. The shares trade on a P/E ratio of 48.9.
What is the Liquidia stock forecast?
The consensus analyst 12-month price target for Liquidia is $107.75, +46.3% from the last close. Of the 7 firms that rated the stock in the last 90 days, 5 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Liquidia stock overvalued or undervalued?
On Gekko’s estimate Liquidia is undervalued: the Sep 28, 2026 close of $73.67 is 16.6% below Gekko Fair Value of $88.32. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Liquidia report earnings next?
Liquidia is expected to report on Nov 2, 2026, before the market opens (34 days away). Analysts expect earnings of $0.90 per share on revenue of $205.9M. Liquidia beat the earnings estimate in 3 of its last 8 reports, moving 12.8% on average across the report.
What is Liquidia’s 52-week high and low?
Liquidia’s 52-week high is $93.61 and its 52-week low is $21.15; it closed at $73.67 on Sep 28, 2026, +228.2% over the past year.
Is Liquidia stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (fair value, smart money and earnings risk), 3 as mixed (trend, gekkoindex and seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Liquidia?
Gekko flagged 2 unusual options signals in Liquidia over the last 30 days, with $1.11M of flagged premium in calls and $41K in puts. The latest, bullish flow, was on Sep 17, 2026 with $783K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Liquidia the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.